Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Most diffuse large B-cell lymphomas arising in CLL patients are clonally related, driving poor outcomes with standard R-CHOP chemotherapy. However, Dr. Koons notes that clonally unrelated cases behave similarly to de novo DLBCL and achieve favorable remissions with R-CHOP alone, whereas clonally related or TP53-mutated cases require novel agent regimens.

Related Insights

Though they sound similar, "double hit" and "double expressor" lymphomas are different entities. "Double hit" refers to genetic rearrangements (MYC and BCL2/BCL6), carrying the worst prognosis. "Double expressor" refers to protein overexpression without genetic rearrangement, conferring an intermediate prognosis that is better than double hit.

Provocative data from a German study showed an 81% complete response rate in untreated, elderly DLBCL patients using a chemotherapy-free regimen of polatuzumab (an ADC), glofitamab (a bispecific), and rituximab. This challenges the decades-long R-CHOP chemotherapy backbone and points to a future of targeted frontline therapies.

The combination of a Notch1 mutation and a specific IGHV stereotype (439 subset 8) creates an extremely high risk for early Richter's transformation in CLL. This finding warrants consideration of immediate combination therapy, even if the patient doesn't meet standard treatment criteria.

Experts view R-mini-CHOP, the standard for older/unfit DLBCL patients, as a poor benchmark that urgently needs to be replaced. Promising chemo-free or chemo-light regimens, like the R-Polo-Glofitamab combination, are seen as the future, aiming to improve outcomes in this vulnerable population without harsh toxicities.

The FRONT-MIND trial's positive result for Tafa-Len-R-CHOP must be contextualized. A key eligibility criterion was a diagnosis-to-treatment interval under 28 days. This selected for patients with rapidly progressing, aggressive disease, creating a higher-risk population than in other trials and likely explaining the R-CHOP arm's weaker performance.

A 15-year follow-up of a SWOG clinical trial shows a significant portion of follicular lymphoma patients treated with R-CHOP remain disease-free. This challenges the long-held belief that the disease is incurable, shifting the paradigm towards a curative intent.

While the first-line Polarix trial suggested Polatuzumab's benefit was greater in ABC-subtype DLBCL, the Polargo trial in relapsed patients found no such difference. Both ABC and GCB subtypes benefited significantly from Polatuzumab's addition. This suggests that in the higher-risk relapse setting, overall disease risk trumps cell of origin as the key determinant of treatment benefit.

Administering initial chemotherapy debulking before introducing bispecific antibodies drastically reduces the incidence of cytokine release syndrome in upfront diffuse large B-cell lymphoma. In a phase 2 trial combining glofitumab with R-CHOP, delaying glofitumab initiation until cycle 3 achieved substantial tumor debulking first. Consequently, cytokine release syndrome dropped to 10% while achieving a 90% complete response rate and 95% MRD negativity at 12 months.

The traditional ABC/GCB classification for DLBCL is flawed. Single-cell sequencing reveals that tumors classified as one type via bulk analysis contain malignant cells of the other subtype. This underlying heterogeneity explains why the distinction is an imperfect predictor and will be replaced by more sophisticated biomarkers like T-cell exhaustion signatures.

Due to a 20% misclassification rate with the Hans algorithm for determining cell of origin, clinicians use an IPI score of 2 or greater as the primary criterion for selecting Polatuzumab-R-CHOP. This avoids potentially giving 1 in 5 patients the wrong therapy based on an imperfect biomarker.